Cardiorenal syndrome – biomarkers and mediators

Czech version

Authors: Jiří Charvát
Authors‘ workplace: Interní klinika 2. LF UK a FN v Motole, Praha
Published in: Vnitř Lék 2016; 62(Suppl 3): 73-76
Category: Reviews

Overview

Symptomatic cardiorenal syndrome presents the clinical condition with the serious prognosis when treatment is hardly succesful. A lot of inflammatory and hormonal factors used as biomarkers in clinical practice participate on the initiation, development and progression of cardiorenal syndrome. It means they play role of mediators between heart and kidney and therefore have the significant position in clinical presentation. However the mutual relations between heart and kidney are formed earlier already in the asymptomatic period. The detection of such changes and its correction is the real challenge. The follow-up of hormonal changes and its modulation might be one of the promising approach.

Key words:
cardiorenal syndrome – biomarker – mediator – inflammatory factors – circulated hormones

Sources

1. McAlister FA, Ezekwitz J, Tonelli M et al. Renal insufficiency and heart failure: prognostic and therapeutic implications from a prospective cohort study. Circulation 2004; 109(8): 1004–1009.

2. Shlipak MG, Massie BM. The clinical challenge of cardiorenal syndrome. Circulation 2004; 110(12): 1514–1517.

3. HillegeHL, Girbes ARJ, de Kam PJ et al. Renal function, neurohormonal activation, and survival in patients with chronic heart failure. Circulation 2000; 102(2): 203–210.

4. Raine AEG, Magreiter R, Brunner FP et al. Report on management of renal failure in Europe. XXII 1991. Nephrol Dial Transplant 1992; 7(Suppl 2): S7-S35.

5. Wali RK, Wang GS, Gottlieb SS et al. Effect of Kidney transplantation on left ventricular systolic dysfunction and congestive heart failure in patients eith end-stage renal disease. J Am Coll Cardiol 2005; 45(7): 1051–1060.

6. Ronco C, Haapio M, House AA et al. Cardiorenal syndrome. J Am Coll Cardiol 2008; 52(19): 1527–1539. Dostupné z DOI: <http://dx.doi.org/10.1016/j.jacc.2008.07.051>.

7. Dunlay SM, Weston SA, Redfield MM et al. Tumour necrosis factor-alfa and mortality in heart failure: a community study. Circulation 2008; 118(6): 625–631. Dostupné z DOI: <http://dx.doi.org/10.1161/CIRCULATIONAHA.107.759191>.

8. Maeda K, Tsutamoto T, Wada A et al. High levels of plasma brain natriuretic peptide and interleukin-6 after optimized treatment for heart failure are independent risk factors for morbidity and mortality in patients with congestive heart failure. J Am Coll Cardiol 2000; 36(5): 1587–1593.

9. Barreto DV, Barreto FC, Liabeuf S et al. Plasma interleukin-6 is independently associated with mortality in both hemodialysis and pre-dialysis patients with chronic kidney disease. Kidney Int 2010; 77(6): 550–556. Dostupné z DOI: <http://dx.doi.org/10.1038/ki.2009.503>.

10. von Haehling S, SchefoldJC, Jankowska E et al. Inflammatory biomarkers in heart failure revisited: much more than innocent bystanders. Heart Fail Clin 2009; 5(4): 549–560. Dostupné z DOI: <http://dx.doi.org/10.1016/j.hfc.2009.04.001>.

11. Damman K, Voors AA, Hillege HL et al. Congestion in chronic systolic heart failure is related to renal dysfunction and increased mortality. Eur J Heart Fail 2010; 12(9): 974–982. Dostupné z DOI: <http://dx.doi.org/10.1093/eurjhf/hfq118>.

12. Tsutamoto T, Hisanaga T, Fukai D et al. Prognostic value of plasma soluble intercellular adhesion molecule-1 and endothelin-1 concentration in patients with chronic congestive heart failure. Am J Cardiol 1995; 76(11): 803–808.

13. Stancanelli B, Malatino LS, Catalioti A et al. Soluble e-selectin is an inverse and independent predictor of left ventricular wall thickness in end-stage renal disease patients Nephron Clin Pract 2010; 114(1): c74–80. Dostupné z DOI: <http://dx.doi.org/10.1159/000252806>.

14. Araujo J, Lourenco P, Azevedo A et al. Prognostic value of high-sensitivity C-reactive protein in heart failure: a systematic review. J Card Fail 2009; 15(3): 256–266. Dostupné z DOI: <http://dx.doi.org/10.1016/j.cardfail.2008.10.030>.

15. Costa E, Lima M, Alves JM et al. Inflammation, T-cell phenotype, and inflammatory cytokines in chronic kidney disease patients under hemodialysis and its relationship to resistence to recombinant human erythropoetin therapy. J Clin Immunol 2008; 28(3): 268–275. Dostupné z DOI: <http://dx.doi.org/10.1007/s10875–007–9168-x>.

16. Longhini C, Mollino C, Fabbian F. Cardiorenal syndrome: still not defined entity. Clin Exp Nephrol 2010; 14(1): 12–21. Dostupné z DOI: <http://dx.doi.org/10.1007/s10157–009–0257–4>.

17. Jessup M, Brozena S. Heart failure. N Engl J Med 2003; 348(20): 2007–2018.

18. Buglioni A, Burneti JC Jr. Pathophysiology and the cardiorenal connection in heart failure, circulating hormones: biomakers or mediators. Clin Chim Acta 2015; 443: 3–8. Dostupné z DOI: <http://dx.doi.org/10.1016/j.cca.2014.10.027>.

19. Becker JR, Chatterjee S, Robinson TY et al. Differential activation of natriuretic peptide receptors modulates cardiomyocyte proliferation during development. Development 2014; 141(2): 335–345. Dostupné z DOI: <http://dx.doi.org/10.1242/dev.100370>.

20. Komajda M, Lam CS. Heart failure with preserved ejection fraction: a clinical dilemma. Eur Heart J 2014; 35(16): 1022–1032. Dostupné z DOI: <http://dx.doi.org/10.1093/eurheartj/ehu067>.

21. Richards AM. The renin-angiotensin-aldosteron system and the cardiac natriuretic peptides. Heart 1996; 76(3 Suppl 3): 3S36–3S44.

22. Melo LG, Veress AT, Ackermann U et al. Chronic regulation of arterial blood pressre by ANP, roleof endogenous vasoactive endothelial factors. Am J Physiol 1998; 275(5 Pt 2): H1826-H1833.

23. Wilkinson IB, Franklin SS, Cockcroft JR. Nitric oxid and the regulation of large artery stifffness: from physiology to pharmacology. Hypertension 2004; 44(2): 112–116.

24. Jackson G, Gibbs CR, Davies MK et al. ABC of heart failure. Pathophysiology. BMJ 2000; 320(7228): 167–170.

25. Weber KT. Aldosteron in congestive heart failure. N Engl J Med 2001; 345(23): 1689–1697.

26. von Lueder TG, Sangaralingham SJ, Wang DH et al. Renin-angiotensin blockade combined with natriuretic peptide system augmentation: novel therapeutic concepts to combat heart failure. Circ Heart Fail 2013; 6(3): 594–605. Dostupné z DOI: <http://dx.doi.org/10.1161/CIRCHEARTFAILURE.112.000289>.

27. Peckova M, Charvat J, Schuck O et al. Plasma adrenomedullin and subclinical cardiorenal syndrome in patients with type 2 diabetes mellitus. J Int Med Res 2012; 40(4): 1552–1559.

28. Rademaker MT, Cameron VA, Charles CJ et al. Adrenomedullin and heart failure. Regul Pept 2003; 112(1–3): 51–60.

29. Chan D, Ng LL. Biomarkers in acute myocardial infarction. BMC Med 2010; 8:34. Dostupné z DOI: <http://dx.doi.org/10.1186/1741–7015–8-34>.

30. Klip I, Voors A, Anker S et al. Prognostic value of mid-regional pro-adrenomedullin in patients with heart failure after acute myocardial infarction. Heart 2001; 97(11): 892–898. Dostupné z DOI: <http://dx.doi.org/10.1136/hrt.2010.210948>.

31. Maisel A, Mueller C, Nowak R et al. Midregion prohormone adrenomedullin and prognosis in patients presenting with acute dyspnea, results of the BACH trials. J Am Coll Cardiol 2011; 58(10): 1057–1067. Dostupné z DOI: <http://dx.doi.org/10.1016/j.jacc.2011.06.006>.

32. Haehling S, Filippatos G, Papassotiriou J et al.Mid-regional pro-adrenomedullin as a novel predictor of mortality in patients with chronic heart faiure. Eur J Heart Fail 2010; 12(5): 484–491. Dostupné z DOI: <http://dx.doi.org/10.1093/eurjhf/hfq031>.

33. Tsumamoto T, Wada A, Maeda K et al. Angiotensin II type 1 receptor antagonist decreases plasma levels of tumour necrosis factor alfa, interleukin-6 and soluble adhesion molecules in patients with chronic heart failure. J Am Call Cardiol 2000;35(3): 714–721.

34. Kalra D. Sivasubramanian N, Mann DL. Angiotensin II induces tumor necrosis factor biosynthesis in the adult mammalian heart through a protein kinase C-dependent pathway. Circulation 2002; 105(18): 2198–2205.

35. Prabhu SD, Chandrasekar B, Murray DR et al. B-adrenergic blockade in developing heart failure: effects on myocardial inflammatory cytokines, nitric oxide, and remodeling. Circulation 2000; 101(17): 2103–2109.

36. Anker S, Coats A. How to RECOVER from RENAIS-SANCE? The signifikance of the results of RECOVER, RENAIS-SANCE, RENEWAL and ATTACH. Int J Cardiol 2002; 86(2–3): 123–130.